Assessment of Post Booster Antibody Responses in UK Infants Given a Reduced Priming Schedule of Meningococcal Serogroup B and 13 Valent Pneumococcal Conjugate Vaccines

Trial Profile

Assessment of Post Booster Antibody Responses in UK Infants Given a Reduced Priming Schedule of Meningococcal Serogroup B and 13 Valent Pneumococcal Conjugate Vaccines

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 08 Jul 2017

At a glance

  • Drugs Meningococcal vaccine group B OMV Novartis (Primary) ; Rotavirus vaccine (Primary) ; DTaP-hepatitis B-poliovirus vaccine; Measles mumps and rubella virus vaccine; Pneumococcal 13-valent CRM197 vaccine conjugate
  • Indications Meningococcal group B infections; Rotavirus infections
  • Focus Pharmacodynamics
  • Acronyms Sched3
  • Most Recent Events

    • 28 Mar 2017 Planned End Date changed from 1 May 2017 to 1 Dec 2017.
    • 28 Mar 2017 Planned primary completion date changed from 1 Oct 2016 to 1 Dec 2017.
    • 28 Mar 2017 Status changed to active, no longer recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top